Bionano Genomics is trying to modernize how labs read and manage tissue and DNA tests, aiming to shift from one-time instrument sales to steadier software and consumables income as healthcare moves toward more personalized treatment. But with slower growth in new system placements and ongoing cash pressure, the big question is whether this strategy can hold up against tight lab budgets and fast-moving competing technologies.Read more
Bionano Genomics sits in fast-moving genetic testing, but cash burn, slow uptake in medical guidelines, and unclear insurance coverage could keep sales and customer growth stuck. The upside hinges on software upgrades and more repeat-use revenue catching on before competition and funding cutbacks squeeze the business further.Read more
Bionano Genomics is trying to move beyond research labs and into everyday hospital use, using its genetic testing tools, software, and AI to create steady repeat sales over time. The upside is a faster move into routine clinical workflows or even a buyout, but falling sales, cash needs, and tougher competition could derail the story.Read more
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
